Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02105 來凱醫藥-B
Listing Date2023/06/29
Listing Price12.410
  • 6.140 -0.460 (-6.970%)    Sink Below Listing Price
  • 15-min delayed, last update: 12/06/2024 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    5 lot
  • One Lot Success Rate

Laekna, Inc. founded in 2016, it is a clinical-stage biotechnology company. It has two Core Products and 14 other pipeline product candidates.


Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other Core Product LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer.


The Group have initiated one registrational clinical trial and another five clinical trials for Core Products LAE002 and LAE001. As of 6 June 2023, it owned 176 patents and patent applications including in-licensed patents and patent applications with global rights.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
No. of Offer Shares63.73M shares
No. of International Offer Shares57.36M shares
No. of HK Offer Shares6.37M shares
Offer Price$12.41
Stock Code2105
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, Haitong International Securities Company Limited, ICBC International Securities Limited, Guotai Junan Securities (Hong Kong) Limited, ABCI Securities Company Limited, Futu Securities International (Hong Kong) Limited, Valuable Capital Limited
Application PeriodJun 16 (Fri) - noon, Jun 21 (Wed)
Price Determination Date--
Result Announcement DateOn or before Jun 28 (Wed)
Result Announcement DateOn or before Jun 28 (Wed)
Result Announcement DateOn or before Jun 28 (Wed)
Dealings in Shares commence onJun 29, 2023. (Thu)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$12.41
NAV / share ($)$2.83 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 12.41, the net proceeds raised would be HKD 708.20M, of which
33% : Advancing the clinical development and approval of one of Core Products LAE001
23.3% : Advancing the clinical development and approval of the other Core Product of the Company, LAE002
20.8% : Accelerating the research and development of other existing pipeline products
9.9% : Improving production capabilities and developing manufacturing capacities
7.6% : Business development activities and enhancing global reach
5.4% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.